Open AccessFirst‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1 : A case report
Author(s) -
Hamai Kosuke,
Tanahashi Hiroki,
Ueno Sayaka,
Konishi Hanae,
Matsumura Mirai,
Nomura Akio,
Nakamoto Kanako,
Isoyama Shoko,
Tanimoto Takuya,
Shoda Hiroyasu,
Ishikawa Nobuhisa
Publication year - 2020
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13436
Subject(s) - medicine , pembrolizumab , lung cancer , mutation , cancer research , immunotherapy , biopsy , lung , oncology , targeted therapy , pd l1 , pathology , cancer , gene , biochemistry , chemistry
A 90‐year‐old female was admitted to our hospital with a history of a dry cough. Chest computed tomography (CT) scan showed a tumor shadow, and CT‐guided lung biopsy revealed squamous cell carcinoma harboring an EGFR mutation. In addition, programmed death‐ligand 1 (PD‐L1) was highly expressed with a tumor proportion score (TPS) of >75%. Pembrolizumab therapy in the first‐line setting was not effective, and the patient died at six months from the first visit. Squamous cell lung cancers (SCLCs) with both EGFR mutation and high expression of PD‐L1 are very rare.